Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Yesterday, Portfolio Recovery Associates Inc. ( PRAA - Analyst Report ) announced a new five-year credit facility worth $600 million, replacing the current one. The company will use the new facility to finance its operations and for investing in growth initiatives.
Portfolio Recovery’s new credit facility offers various alternatives for borrowing rates for the loans taken under it. These alternatives are similar to those offered under the company’s previous credit facility. However, Portfolio Recovery plans to mainly take loans based on the LIBOR rate, with a spread of about 250 basis points.
The new credit facility will substantially increase the borrowing capacity of the company as Portfolio Recovery had only $214.5 million as the remaining borrowing availability under its old credit facility as of Sep 30, 2012. Thus, the new facility will boost the financial flexibility of the company, thereby allowing it to increase its expenditure on business investments. Moreover, the company expects the new facility to bring down its cost of funds.
Further, the accordion feature of the new credit facility offers Portfolio Recovery the option to apply for an extension of the borrowing capacity for an amount up to $250 million. However, the company intends to keep its borrowings under check, and hence will cautiously evaluate all investment opportunities to invest only in those portfolios, businesses or products that offer adequate returns.
Peer Encore Capital Group, Inc. ( ECPG - Snapshot Report ) also announced the amendment of its old $555.5 million revolving credit facility in November 2012. The old facility was set to expire by the end of 2013. The amended facility comprises a $425 million revolving credit facility valid for 5 years along with a $100 million term note due in November 2017 and a $50 million term note due in November 2015. Moreover, Encore Capital has the option of increasing the borrowing limit by $200 million using the accordion feature of the credit facility.
Portfolio Recovery currently carries a Zacks #3 Rank (Hold). We maintain a long-term ‘Neutral’ recommendation on the stock. Encore Capital also carries the same Zacks Rank.
Read the full Analyst Report on PRAA
Read the full Snapshot Report on ECPG